Top 5 Stocks to Buy Now
→ SpaceX will crumble without these 5 companies (From InvestPub) (Ad)tc pixel Free QLGN Stock Alerts

Qualigen Therapeutics (QLGN) Competitors

Qualigen Therapeutics logo
$1.46 +0.03 (+2.10%)
As of 06/18/2026
Compare

QLGN vs. CURX, IMNN, HCWB, NXTC, and NCNA

Should you buy Qualigen Therapeutics stock or one of its competitors? MarketBeat compares Qualigen Therapeutics with other companies and stocks that may be similar based on industry, sector, market capitalization, business model, investor interest, or shared news coverage. Companies and stocks commonly compared with Qualigen Therapeutics include Curanex Pharmaceuticals (CURX), Imunon (IMNN), HCW Biologics (HCWB), NextCure (NXTC), and NuCana (NCNA). These companies are all part of the "pharmaceutical products" industry.

How does Qualigen Therapeutics compare to Curanex Pharmaceuticals?

Qualigen Therapeutics (NASDAQ:QLGN) and Curanex Pharmaceuticals (NASDAQ:CURX) are both small-cap pharmaceutical products companies, but which is the better business? We will compare the two companies based on the strength of their institutional ownership, media sentiment, profitability, risk, earnings, analyst recommendations, dividends and valuation.

In the previous week, Qualigen Therapeutics' average media sentiment score of 0.00 equaled Curanex Pharmaceuticals'average media sentiment score.

Company Overall Sentiment
Qualigen Therapeutics Neutral
Curanex Pharmaceuticals Neutral

Qualigen Therapeutics' return on equity of 0.00% beat Curanex Pharmaceuticals' return on equity.

Company Net Margins Return on Equity Return on Assets
Qualigen TherapeuticsN/A N/A -202.16%
Curanex Pharmaceuticals N/A -85.41%-82.11%

3.2% of Qualigen Therapeutics shares are owned by institutional investors. 1.8% of Qualigen Therapeutics shares are owned by company insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a company is poised for long-term growth.

Curanex Pharmaceuticals is trading at a lower price-to-earnings ratio than Qualigen Therapeutics, indicating that it is currently the more affordable of the two stocks.

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Qualigen TherapeuticsN/AN/A-$6.26M-$7.50N/A
Curanex PharmaceuticalsN/AN/A-$4.22M-$0.27N/A

Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
Qualigen Therapeutics
1 Sell rating(s)
0 Hold rating(s)
0 Buy rating(s)
0 Strong Buy rating(s)
1.00
Curanex Pharmaceuticals
1 Sell rating(s)
0 Hold rating(s)
0 Buy rating(s)
0 Strong Buy rating(s)
1.00

Summary

Qualigen Therapeutics beats Curanex Pharmaceuticals on 4 of the 7 factors compared between the two stocks.

How does Qualigen Therapeutics compare to Imunon?

Qualigen Therapeutics (NASDAQ:QLGN) and Imunon (NASDAQ:IMNN) are both small-cap medical companies, but which is the superior stock? We will compare the two businesses based on the strength of their analyst recommendations, risk, profitability, dividends, earnings, valuation, institutional ownership and media sentiment.

3.2% of Qualigen Therapeutics shares are owned by institutional investors. Comparatively, 4.5% of Imunon shares are owned by institutional investors. 1.8% of Qualigen Therapeutics shares are owned by company insiders. Comparatively, 2.8% of Imunon shares are owned by company insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a stock will outperform the market over the long term.

Qualigen Therapeutics has a beta of 0.24, suggesting that its stock price is 76% less volatile than the broader market. Comparatively, Imunon has a beta of 1.95, suggesting that its stock price is 95% more volatile than the broader market.

Imunon has a consensus price target of $10.00, indicating a potential upside of 449.45%. Given Imunon's stronger consensus rating and higher probable upside, analysts clearly believe Imunon is more favorable than Qualigen Therapeutics.

Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
Qualigen Therapeutics
1 Sell rating(s)
0 Hold rating(s)
0 Buy rating(s)
0 Strong Buy rating(s)
1.00
Imunon
1 Sell rating(s)
0 Hold rating(s)
1 Buy rating(s)
0 Strong Buy rating(s)
2.00

In the previous week, Qualigen Therapeutics' average media sentiment score of 0.00 equaled Imunon'saverage media sentiment score.

Company Overall Sentiment
Qualigen Therapeutics Neutral
Imunon Neutral

Qualigen Therapeutics' return on equity of 0.00% beat Imunon's return on equity.

Company Net Margins Return on Equity Return on Assets
Qualigen TherapeuticsN/A N/A -202.16%
Imunon N/A -341.23%-153.79%

Imunon is trading at a lower price-to-earnings ratio than Qualigen Therapeutics, indicating that it is currently the more affordable of the two stocks.

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Qualigen TherapeuticsN/AN/A-$6.26M-$7.50N/A
ImunonN/AN/A-$14.49M-$5.16N/A

Summary

Imunon beats Qualigen Therapeutics on 8 of the 11 factors compared between the two stocks.

How does Qualigen Therapeutics compare to HCW Biologics?

HCW Biologics (NASDAQ:HCWB) and Qualigen Therapeutics (NASDAQ:QLGN) are both small-cap medical companies, but which is the superior investment? We will contrast the two businesses based on the strength of their institutional ownership, earnings, dividends, profitability, risk, valuation, media sentiment and analyst recommendations.

In the previous week, HCW Biologics had 3 more articles in the media than Qualigen Therapeutics. MarketBeat recorded 3 mentions for HCW Biologics and 0 mentions for Qualigen Therapeutics. HCW Biologics' average media sentiment score of 0.58 beat Qualigen Therapeutics' score of 0.00 indicating that HCW Biologics is being referred to more favorably in the media.

Company Overall Sentiment
HCW Biologics Positive
Qualigen Therapeutics Neutral

3.0% of HCW Biologics shares are owned by institutional investors. Comparatively, 3.2% of Qualigen Therapeutics shares are owned by institutional investors. 9.1% of HCW Biologics shares are owned by company insiders. Comparatively, 1.8% of Qualigen Therapeutics shares are owned by company insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a stock will outperform the market over the long term.

Qualigen Therapeutics has a net margin of 0.00% compared to HCW Biologics' net margin of -34.73%. Qualigen Therapeutics' return on equity of 0.00% beat HCW Biologics' return on equity.

Company Net Margins Return on Equity Return on Assets
HCW Biologics-34.73% -486.87% -29.19%
Qualigen Therapeutics N/A N/A -202.16%

HCW Biologics currently has a consensus target price of $5.00, indicating a potential upside of 362.96%. Given HCW Biologics' stronger consensus rating and higher probable upside, research analysts plainly believe HCW Biologics is more favorable than Qualigen Therapeutics.

Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
HCW Biologics
1 Sell rating(s)
0 Hold rating(s)
1 Buy rating(s)
0 Strong Buy rating(s)
2.00
Qualigen Therapeutics
1 Sell rating(s)
0 Hold rating(s)
0 Buy rating(s)
0 Strong Buy rating(s)
1.00

HCW Biologics has a beta of 2.21, suggesting that its stock price is 121% more volatile than the broader market. Comparatively, Qualigen Therapeutics has a beta of 0.24, suggesting that its stock price is 76% less volatile than the broader market.

Qualigen Therapeutics has lower revenue, but higher earnings than HCW Biologics. Qualigen Therapeutics is trading at a lower price-to-earnings ratio than HCW Biologics, indicating that it is currently the more affordable of the two stocks.

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
HCW Biologics$6.59M1.17-$7.96M-$9.46N/A
Qualigen TherapeuticsN/AN/A-$6.26M-$7.50N/A

Summary

HCW Biologics beats Qualigen Therapeutics on 10 of the 15 factors compared between the two stocks.

How does Qualigen Therapeutics compare to NextCure?

NextCure (NASDAQ:NXTC) and Qualigen Therapeutics (NASDAQ:QLGN) are both small-cap medical companies, but which is the superior investment? We will contrast the two companies based on the strength of their profitability, dividends, institutional ownership, valuation, earnings, risk, analyst recommendations and media sentiment.

In the previous week, NextCure's average media sentiment score of 2.00 beat Qualigen Therapeutics' score of 0.00 indicating that NextCure is being referred to more favorably in the media.

Company Overall Sentiment
NextCure Very Positive
Qualigen Therapeutics Neutral

NextCure presently has a consensus price target of $23.00, suggesting a potential upside of 1,038.61%. Given NextCure's stronger consensus rating and higher probable upside, analysts plainly believe NextCure is more favorable than Qualigen Therapeutics.

Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
NextCure
1 Sell rating(s)
1 Hold rating(s)
3 Buy rating(s)
0 Strong Buy rating(s)
2.40
Qualigen Therapeutics
1 Sell rating(s)
0 Hold rating(s)
0 Buy rating(s)
0 Strong Buy rating(s)
1.00

Qualigen Therapeutics is trading at a lower price-to-earnings ratio than NextCure, indicating that it is currently the more affordable of the two stocks.

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
NextCureN/AN/A-$55.84M-$17.19N/A
Qualigen TherapeuticsN/AN/A-$6.26M-$7.50N/A

42.7% of NextCure shares are owned by institutional investors. Comparatively, 3.2% of Qualigen Therapeutics shares are owned by institutional investors. 11.9% of NextCure shares are owned by insiders. Comparatively, 1.8% of Qualigen Therapeutics shares are owned by insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a stock is poised for long-term growth.

Qualigen Therapeutics' return on equity of 0.00% beat NextCure's return on equity.

Company Net Margins Return on Equity Return on Assets
NextCureN/A -186.96% -124.62%
Qualigen Therapeutics N/A N/A -202.16%

NextCure has a beta of 1.3, meaning that its stock price is 30% more volatile than the broader market. Comparatively, Qualigen Therapeutics has a beta of 0.24, meaning that its stock price is 76% less volatile than the broader market.

Summary

NextCure beats Qualigen Therapeutics on 9 of the 12 factors compared between the two stocks.

How does Qualigen Therapeutics compare to NuCana?

Qualigen Therapeutics (NASDAQ:QLGN) and NuCana (NASDAQ:NCNA) are both small-cap medical companies, but which is the superior stock? We will compare the two companies based on the strength of their dividends, analyst recommendations, risk, profitability, institutional ownership, media sentiment, valuation and earnings.

In the previous week, NuCana had 1 more articles in the media than Qualigen Therapeutics. MarketBeat recorded 1 mentions for NuCana and 0 mentions for Qualigen Therapeutics. Qualigen Therapeutics' average media sentiment score of 0.00 equaled NuCana'saverage media sentiment score.

Company Overall Sentiment
Qualigen Therapeutics Neutral
NuCana Neutral

NuCana is trading at a lower price-to-earnings ratio than Qualigen Therapeutics, indicating that it is currently the more affordable of the two stocks.

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Qualigen TherapeuticsN/AN/A-$6.26M-$7.50N/A
NuCanaN/AN/A-$38.71M-$2.98N/A

Qualigen Therapeutics' return on equity of 0.00% beat NuCana's return on equity.

Company Net Margins Return on Equity Return on Assets
Qualigen TherapeuticsN/A N/A -202.16%
NuCana N/A -153.61%-116.03%

Qualigen Therapeutics has a beta of 0.24, indicating that its stock price is 76% less volatile than the broader market. Comparatively, NuCana has a beta of 2.18, indicating that its stock price is 118% more volatile than the broader market.

3.2% of Qualigen Therapeutics shares are owned by institutional investors. Comparatively, 44.0% of NuCana shares are owned by institutional investors. 1.8% of Qualigen Therapeutics shares are owned by company insiders. Comparatively, 31.2% of NuCana shares are owned by company insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a stock is poised for long-term growth.

Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
Qualigen Therapeutics
1 Sell rating(s)
0 Hold rating(s)
0 Buy rating(s)
0 Strong Buy rating(s)
1.00
NuCana
1 Sell rating(s)
0 Hold rating(s)
0 Buy rating(s)
0 Strong Buy rating(s)
1.00

Summary

NuCana beats Qualigen Therapeutics on 6 of the 9 factors compared between the two stocks.

Get Qualigen Therapeutics News Delivered to You Automatically

Sign up to receive the latest news and ratings for QLGN and its competitors with MarketBeat's FREE daily newsletter.

Subscribe Now
SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding QLGN and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
Skip Chart

Media Sentiment Over Time

This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Skip Chart

QLGN vs. The Competition

Export
MetricQualigen TherapeuticsMED IndustryMedical SectorNASDAQ Exchange
Market Cap$2.48M$2.98B$6.43B$12.60B
Dividend YieldN/A1.78%2.68%5.81%
P/E Ratio-0.1918.6724.7524.44
Price / SalesN/A310.39529.79110.16
Price / CashN/A56.4245.0755.09
Price / Book-0.354.0410.806.58
Net Income-$6.26M$75.79M$3.57B$337.17M
7 Day Performance5.04%0.38%0.72%0.83%
1 Month Performance13.18%-0.14%0.41%2.25%
1 Year Performance-59.49%26.02%29.34%36.14%

Qualigen Therapeutics Competitors List

Export
CompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)
QLGN
Qualigen Therapeutics
N/A$1.46
+2.1%		N/A-59.5%$2.48MN/AN/A50
CURX
Curanex Pharmaceuticals
0.839 of 5 stars		$0.33
+6.7%		N/AN/A$8.67MN/AN/AN/A
IMNN
Imunon
3.0622 of 5 stars		$1.98
-2.0%		$10.00
+405.1%		-88.1%$8.49MN/AN/A30
HCWB
HCW Biologics
3.262 of 5 stars		$1.21
+2.5%		$5.00
+313.2%		-76.4%$8.45M$50KN/A40
NXTC
NextCure
3.442 of 5 stars		$2.23
-4.3%		$23.00
+931.4%		-64.2%$8.42MN/AN/A90

Related Companies and Tools

Related Companies
Top 10 Stock Comparisons

This page (NASDAQ:QLGN) was last updated on 6/21/2026 by MarketBeat.com Staff.
From Our Partners
Trump's gold order: the announcement they won't put on the front page
On August 15, 1971, Nixon interrupted prime-time television and ended the gold standard in 15 minutes - no deb...
Reagan Gold Group | Sponsoredtc pixel
Louis Navellier: My #1 AI stock for 2026 (name & ticker inside)
Louis Navellier's Stock Grader system helped him flag Nvidia before its 82,000% run and has identified the top...
InvestorPlace | Sponsoredtc pixel
Trump Takes Emergency Action - Plus Elon Musk's New Venture
Elon Musk has quietly launched a new venture - one that has nothing to do with rockets, EVs, or Neuralink. Tru...
Altimetry | Sponsoredtc pixel
This is the worst news for stocks in 50 years
Goldman Sachs and Morgan Stanley are issuing a rare warning: what's ahead for U.S. stocks could be the worst e...
TradeSmith | Sponsoredtc pixel
A huge SpaceX error just led one stock to 3X move!
SPCE surged roughly 300% in a single week after investors hunting SpaceX exposure piled into the wrong ticker....
InvestPub | Sponsoredtc pixel
CODE RED: AI Meltdown Imminent?
After correctly predicting the 2008 and 2020 stock market meltdowns, I believe this AI company is about to tri...
Paradigm Press | Sponsoredtc pixel
The roadshow starts Monday. This stock isn't ready.
The SpaceX roadshow kicks off June 8. Goldman Sachs, the lead underwriter, will present the full S-1 to the wo...
Behind the Markets | Sponsoredtc pixel
Hey, it's Jon Najarian. The SpaceX IPO is right around the corner. But I discovered Elon may have something BIGGER planned. Check this out before June 9th...
After being invited to the SpaceX launch headquarters in Cape Canaveral from one of Elon's top lobbyists… Hall...
Banyan Hill Publishing | Sponsoredtc pixel